# Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers

> **NCT07113106** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 48 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** CD40.Pan.CoV Low dose(0.25mg)
- **BIOLOGICAL:** CD40.Pan.CoV Low dose (0,25mg) adjuvanted with Hiltonol®
- **BIOLOGICAL:** CD40.Pan.CoV High dose (1mg)
- **BIOLOGICAL:** CD40.Pan.CoV High dose (1mg) adjuvanted with Hiltonol®

## Key facts

- **NCT ID:** NCT07113106
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-18
- **Primary completion:** 2026-10-08
- **Final completion:** 2027-06-25
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07113106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07113106, "Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07113106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*